최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Drug design, development and therapy, v.11, 2017년, pp.1409 - 1416
Kim, Tae-Eun (Department of Clinical Pharmacology, Konkuk University Medical Center, Seoul) , Ha, Na (Center for Clinical Pharmacology, Biomedical Research Institute, Chonbuk National University Hospital, Jeonju, Jeonbuk) , Kim, Yunjeong (Center for Clinical Pharmacology, Biomedical Research Institute, Chonbuk National University Hospital, Jeonju, Jeonbuk) , Kim, Hyunsook (Department of Clinical Pharmacology, Konkuk University Medical Center, Seoul) , Lee, Jae Wook (Nephrology Clinic, National Cancer Center, Goyang, Gyeonggi-do) , Jeon, Ji-Young (Center for Clinical Pharmacology, Biomedical Research Institute, Chonbuk National University Hospital, Jeonju, Jeonbuk) , Kim, Min-Gul (Center for Clinical Pharmacology, Biomedical Research Institute, Chonbuk National University Hospital, Jeonju, Jeonbuk)
Previous in vitro studies have demonstrated the inhibitory effect of green tea on drug transporters. Because rosuvastatin, a lipid-lowering drug widely used for the prevention of cardiovascular events, is a substrate for many drug transporters, there is a possibility that there is interaction betwee...
1 Werba JP Misaka S Giroli MG Overview of green tea interaction with cardiovascular drugs Curr Pharm Des 2015 21 9 1213 1219 25312732
2 Yang CS Wang X Lu G Picinich SC Cancer prevention by tea: animal studies, molecular mechanisms and human relevance Nat Rev Cancer 2009 9 6 429 439 19472429
3 Amiot MJ Riva C Vinet A Effects of dietary polyphenols on metabolic syndrome features in humans: a systematic review Obes Rev 2016 17 7 573 586 27079631
4 Kuriyama S Shimazu T Ohmori K Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study JAMA 2006 296 10 1255 1265 16968850
5 Hartley L Flowers N Holmes J Green and black tea for the primary prevention of cardiovascular disease Cochrane Database Syst Rev 2013 6 CD009934
6 Pang J Zhang Z Zheng TZ Green tea consumption and risk of cardiovascular and ischemic related diseases: a meta-analysis Int J Cardiol 2016 202 967 974 26318390
7 Wang ZM Zhou B Wang YS Black and green tea consumption and the risk of coronary artery disease: a meta-analysis Am J Clin Nutr 2011 93 3 506 515 21248184
8 Graham HN Green tea composition, consumption, and polyphenol chemistry Prev Med 1992 21 3 334 350 1614995
9 Roth M Timmermann BN Hagenbuch B Interactions of green tea catechins with organic anion-transporting polypeptides Drug Metab Dispos 2011 39 5 920 926 21278283
10 Knop J Misaka S Singer K Inhibitory effects of green tea and (-)-epigallocatechin gallate on transport by OATP1B1, OATP1B3, OCT1, OCT2, MATE1, MATE2-K and P-glycoprotein PLoS One 2015 10 10 e0139370 26426900
11 Misaka S Yatabe J Muller F Green tea ingestion greatly reduces plasma concentrations of nadolol in healthy subjects Clin Pharmacol Ther 2014 95 4 432 438 24419562
12 Ho RH Tirona RG Leake BF Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics Gastroenterology 2006 130 6 1793 1806 16697742
13 Kitamura S Maeda K Wang Y Sugiyama Y Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin Drug Metab Dispos 2008 36 10 2014 2023 18617601
14 Varma MV Rotter CJ Chupka J pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1 Mol Pharm 2011 8 4 1303 1313 21710988
15 Windass AS Lowes S Wang Y Brown CD The contribution of organic anion transporters OAT1 and OAT3 to the renal uptake of rosuvastatin J Pharmacol Exp Ther 2007 322 3 1221 1227 17585018
16 Lee HK Hu M Lui S Ho CS Wong CK Tomlinson B Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients Pharmacogenomics 2013 14 11 1283 1294 23930675
17 Tomlinson B Hu M Lee VW ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin Clin Pharmacol Ther 2010 87 5 558 562 20130569
18 Zhang W Yu BN He YJ Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males Clin Chim Acta 2006 373 1–2 99 103 16784736
19 Chasman DI Giulianini F MacFadyen J Barratt BJ Nyberg F Ridker PM Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial Circ Cardiovasc Genet 2012 5 2 257 264 22331829
20 Richards JC Lonac MC Johnson TK Schweder MM Bell C Epigallocatechin-3-gallate increases maximal oxygen uptake in adult humans Med Sci Sports Exerc 2010 42 4 739 744 19952844
21 Ullmann U Haller J Bakker GC Brink EJ Weber P Epigallocatechin gallate (EGCG) (TEAVIGO) does not impair nonhaem-iron absorption in man Phytomedicine 2005 12 6–7 410 415 16008116
22 Lee JH Chong WS Park JK Park TS Chae SW Kim MG Rooibos™: automated schedule broadcast software for clinical pharmacology studies Transl Clin Pharmacol 2016 24 127 131
23 Chen L Lee MJ Li H Yang CS Absorption, distribution, elimination of tea polyphenols in rats Drug Metab Dispos 1997 25 9 1045 1050 9311619
24 Chow HH Cai Y Hakim IA Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals Clin Cancer Res 2003 9 9 3312 3319 12960117
25 Yang CS Lambert JD Ju J Lu G Sang S Tea and cancer prevention: molecular mechanisms and human relevance Toxicol Appl Pharmacol 2007 224 3 265 273 17234229
26 Chow HH Cai Y Alberts DS Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E Cancer Epidemiol Biomarkers Prev 2001 10 1 53 58 11205489
※ AI-Helper는 부적절한 답변을 할 수 있습니다.